Novo Nordisk's stock is down, the CEO is out, and Eli Lilly is ascendant. Danish drugmaker projects confidence, but R&D veterans say caution carried a cost.
Outgrowing your competition may not be that difficult, but outgrowing your own country is a different story. That's how you can define the story of the Danish pharmaceutical company Novo Nordisk. Thanks to its drugs Ozempic (primarily for diabetes) and Wegovy (for obesity), it managed to outgrow the economy of its own country,...